Physician profile
Jonathan Chen
NPI 1154813525
$15,388.16
in general payments reported to CMS, 2019-2025
24 companies · $2,879 in 2025
The $2,879 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $105 · 2021: $95.60 · 2022: $850 · 2023: $2,042 · 2024: $7,864 · 2025: $2,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $839 · Gift: $470 · Honoraria: $350 · Entertainment: $247 · Consulting Fee: $100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,120.99 |
| Travel and Lodging | $839.00 |
| Gift | $470.00 |
| Honoraria | $350.00 |
| Entertainment | $246.51 |
| Consulting Fee | $100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $4,161.70 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $1,597.28 | 2019-2025 | Acuvue |
| Valley Contax, INC. | $1,245.44 | 2019 | |
| Coopervision INC. | $1,046.17 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Harrow Eye, LLC | $833.33 | 2024-2025 | Vevye |
| Alcon Vision LLC | $771.47 | 2019-2025 | Precision7, Rocklatan, Eysuvis |
| Sun Pharmaceutical Industries INC. | $753.82 | 2020-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $700.77 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $652.53 | 2024-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Oyster Point Pharma, INC. | $491.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $474.99 | 2023-2024 | Ce-Marked Kxla System |
| Visionary Optics LLC | $470.00 | 2025 | |
| Optos, INC. | $246.51 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $235.61 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $187.05 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $185.57 | 2025 | |
| Abbvie INC. | $176.26 | 2022-2023 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.85 | 2019 | |
| Rxsight INC | $79.30 | 2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Allergan, INC. | $69.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.09 | 2025 | |
| Mallinckrodt Hospital Products INC. | $22.57 | 2020 | |
| Alcon Research LLC | $20.20 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.